478 related articles for article (PubMed ID: 29143824)
1. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.
Wartewig T; Kurgyis Z; Keppler S; Pechloff K; Hameister E; Öllinger R; Maresch R; Buch T; Steiger K; Winter C; Rad R; Ruland J
Nature; 2017 Dec; 552(7683):121-125. PubMed ID: 29143824
[TBL] [Abstract][Full Text] [Related]
2. PD-1 Tumor Suppressor Signaling in T Cell Lymphomas.
Wartewig T; Ruland J
Trends Immunol; 2019 May; 40(5):403-414. PubMed ID: 30979616
[TBL] [Abstract][Full Text] [Related]
3. PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma.
Wartewig T; Daniels J; Schulz M; Hameister E; Joshi A; Park J; Morrish E; Venkatasubramani AV; Cernilogar FM; van Heijster FHA; Hundshammer C; Schneider H; Konstantinidis F; Gabler JV; Klement C; Kurniawan H; Law C; Lee Y; Choi S; Guitart J; Forne I; Giustinani J; Müschen M; Jain S; Weinstock DM; Rad R; Ortonne N; Schilling F; Schotta G; Imhof A; Brenner D; Choi J; Ruland J
Nat Cancer; 2023 Oct; 4(10):1508-1525. PubMed ID: 37723306
[TBL] [Abstract][Full Text] [Related]
4. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint molecule expression by B and T cell lymphomas in dogs.
Hartley G; Elmslie R; Dow S; Guth A
Vet Comp Oncol; 2018 Sep; 16(3):352-360. PubMed ID: 29380929
[TBL] [Abstract][Full Text] [Related]
6. Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice.
Liu X; Karnell JL; Yin B; Zhang R; Zhang J; Li P; Choi Y; Maltzman JS; Pear WS; Bassing CH; Turka LA
J Clin Invest; 2010 Jul; 120(7):2497-507. PubMed ID: 20516645
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
Tiemann M; Samoilova V; Atiakshin D; Buchwalow I
BMC Res Notes; 2020 Mar; 13(1):139. PubMed ID: 32143684
[TBL] [Abstract][Full Text] [Related]
8. Large B-cell lymphomas poor in B cells and rich in PD-1+ T cells can mimic T-cell lymphomas.
Ohgami RS; Zhao S; Natkunam Y
Am J Clin Pathol; 2014 Aug; 142(2):150-6. PubMed ID: 25015854
[TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
10. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
[TBL] [Abstract][Full Text] [Related]
11. Premalignant PTEN-deficient thymocytes activate microRNAs miR-146a and miR-146b as a cellular defense against malignant transformation.
Burger ML; Xue L; Sun Y; Kang C; Winoto A
Blood; 2014 Jun; 123(26):4089-100. PubMed ID: 24735967
[TBL] [Abstract][Full Text] [Related]
12. Histone H2AX suppresses translocations in lymphomas of Eμ-c-Myc transgenic mice that contain a germline amplicon of tumor-promoting genes.
Fusello A; Horowitz J; Yang-Iott K; Brady BL; Yin B; Rowh MA; Rappaport E; Bassing CH
Cell Cycle; 2013 Sep; 12(17):2867-75. PubMed ID: 23966158
[TBL] [Abstract][Full Text] [Related]
13. Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis.
Haney SL; Hlady RA; Opavska J; Klinkebiel D; Pirruccello SJ; Dutta S; Datta K; Simpson MA; Wu L; Opavsky R
Oncogene; 2015 Oct; 34(43):5436-5446. PubMed ID: 25639876
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells.
Maeda N; Maruhashi T; Sugiura D; Shimizu K; Okazaki IM; Okazaki T
J Biol Chem; 2019 Dec; 294(52):19896-19906. PubMed ID: 31723031
[TBL] [Abstract][Full Text] [Related]
15. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma.
Dorfman DM; Brown JA; Shahsafaei A; Freeman GJ
Am J Surg Pathol; 2006 Jul; 30(7):802-10. PubMed ID: 16819321
[TBL] [Abstract][Full Text] [Related]
16. Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma.
Rao S; Cai KQ; Stadanlick JE; Greenberg-Kushnir N; Solanki-Patel N; Lee SY; Fahl SP; Testa JR; Wiest DL
Cancer Res; 2016 Jun; 76(11):3387-96. PubMed ID: 27197189
[TBL] [Abstract][Full Text] [Related]
17. T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus.
Hagenbeek TJ; Spits H
Leukemia; 2008 Mar; 22(3):608-19. PubMed ID: 18046443
[TBL] [Abstract][Full Text] [Related]
18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
19. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice.
Yassin M; Sadowska Z; Djurhuus D; Nielsen B; Tougaard P; Olsen J; Pedersen AE
Immunology; 2019 Sep; 158(1):35-46. PubMed ID: 31429085
[TBL] [Abstract][Full Text] [Related]
20. PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation.
Shimizu K; Sugiura D; Okazaki IM; Maruhashi T; Takegami Y; Cheng C; Ozaki S; Okazaki T
Mol Cell; 2020 Mar; 77(5):937-950.e6. PubMed ID: 31926851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
